Your browser is no longer supported. Please, upgrade your browser.
ALXO [NASD]
ALX Oncology Holdings Inc.
Index- P/E- EPS (ttm)-2.06 Insider Own1.60% Shs Outstand40.25M Perf Week0.14%
Market Cap3.26B Forward P/E- EPS next Y-2.34 Insider Trans-24.68% Shs Float24.87M Perf Month15.67%
Income-60.00M PEG- EPS next Q-0.47 Inst Own83.40% Short Float9.67% Perf Quarter31.24%
Sales0.53M P/S6193.79 EPS this Y-311.10% Inst Trans-0.36% Short Ratio8.01 Perf Half Y23.37%
Book/sh10.06 P/B7.73 EPS next Y-31.50% ROA-15.50% Target Price97.29 Perf Year103.58%
Cash/sh9.77 P/C7.96 EPS next 5Y- ROE-15.90% 52W Range32.51 - 117.45 Perf YTD-9.73%
Dividend- P/FCF- EPS past 5Y- ROI-10.40% 52W High-36.30% Beta-
Dividend %- Quick Ratio29.50 Sales past 5Y- Gross Margin- 52W Low130.14% ATR3.76
Employees29 Current Ratio29.50 Sales Q/Q- Oper. Margin- RSI (14)54.49 Volatility4.13% 5.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.00% Profit Margin- Rel Volume2.08 Prev Close77.81
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume300.30K Price74.82
Recom1.90 SMA200.68% SMA5013.28% SMA2007.53% Volume154,218 Change-3.84%
May-05-21Resumed Credit Suisse Outperform $98
Apr-26-21Resumed Credit Suisse Outperform $98
Apr-06-21Initiated UBS Buy
Feb-10-21Initiated H.C. Wainwright Buy $100
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Aug-11-20Initiated Credit Suisse Outperform $53
Aug-11-20Initiated Cantor Fitzgerald Overweight $64
Sep-16-21 07:00AM  
Sep-14-21 07:00AM  
Sep-07-21 07:00AM  
Aug-27-21 06:55AM  
Aug-12-21 04:05PM  
Jul-28-21 07:00AM  
Jul-15-21 12:00PM  
01:36AM  
Jul-12-21 06:07AM  
Jul-06-21 09:15AM  
Jul-03-21 07:15AM  
Jun-14-21 07:00AM  
Jun-10-21 07:00AM  
May-18-21 07:00AM  
May-17-21 04:05PM  
May-10-21 07:00AM  
Apr-21-21 04:05PM  
Apr-16-21 01:41AM  
Apr-05-21 07:00AM  
Mar-18-21 04:05PM  
Mar-15-21 07:00AM  
Mar-05-21 08:15AM  
Mar-04-21 04:05PM  
Mar-03-21 08:34AM  
Mar-02-21 07:00AM  
Feb-10-21 10:05AM  
Jan-16-21 01:12AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-17-20 07:00AM  
Dec-14-20 04:05PM  
Dec-11-20 10:55PM  
Dec-09-20 10:26PM  
Dec-07-20 04:08PM  
10:00AM  
07:00AM  
Nov-24-20 07:00AM  
Nov-12-20 04:05PM  
Nov-09-20 08:10AM  
Nov-05-20 07:00AM  
Nov-02-20 07:00AM  
Oct-28-20 07:00AM  
Oct-14-20 04:25PM  
Oct-06-20 07:00AM  
Sep-22-20 07:00AM  
Sep-17-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 04:05PM  
Jul-21-20 04:05PM  
Jul-17-20 04:17PM  
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARCIA PETER SChief Financial OfficerSep 17Option Exercise4.0811,34546,28820,676Sep 17 08:45 PM
GARCIA PETER SChief Financial OfficerSep 17Sale78.9611,345895,8119,331Sep 17 08:45 PM
GARCIA PETER SChief Financial OfficerSep 16Option Exercise4.081,4265,81810,757Sep 17 08:45 PM
GARCIA PETER SChief Financial OfficerSep 16Sale80.431,426114,6959,331Sep 17 08:45 PM
Randolph SophiaChief Medical OfficerSep 10Sale77.667,387573,670156,815Sep 13 07:10 PM
GARCIA PETER SChief Financial OfficerAug 23Option Exercise4.0860,000244,80069,331Aug 24 06:17 PM
GARCIA PETER SChief Financial OfficerAug 23Sale74.1560,0004,448,7629,331Aug 24 06:17 PM
Pons JaumePresident & CEOAug 19Sale61.2816,7001,023,340477,998Aug 20 08:07 PM
GARCIA PETER SChief Financial OfficerAug 17Option Exercise4.0810,00040,80019,331Aug 18 07:11 PM
GARCIA PETER SChief Financial OfficerAug 17Sale66.2310,000662,2999,331Aug 18 07:11 PM
Randolph SophiaChief Medical OfficerAug 10Sale64.637,387477,439164,202Aug 11 04:11 PM
Pons JaumePresident & CEOJul 19Sale54.5716,700911,245494,546Jul 20 04:12 PM
Randolph SophiaChief Medical OfficerJul 12Sale54.907,387405,527171,589Jul 14 04:50 PM
Pons JaumePresident & CEOJun 21Sale58.5916,700978,480511,246Jun 22 04:26 PM
Randolph SophiaChief Medical OfficerJun 10Sale60.887,387449,697178,976Jun 14 04:08 PM
Pons JaumePresident & CEOMay 19Sale55.7116,700930,276527,946May 20 07:52 PM
Pons JaumePresident & CEOApr 19Sale57.6316,700962,433544,646Apr 21 04:14 PM
Randolph SophiaChief Medical OfficerApr 12Sale59.437,387438,978193,750Apr 13 04:05 PM
Pons JaumePresident & CEOMar 25Option Exercise0.9910,0009,900561,346Mar 26 09:39 PM
Pons JaumePresident and CEOMar 22Option Exercise1.9116,70031,897568,046Mar 24 04:05 PM
Pons JaumePresident and CEOMar 22Sale68.4916,7001,143,860551,346Mar 24 04:05 PM
Randolph SophiaChief Medical OfficerMar 10Sale74.347,387549,173201,137Mar 12 09:39 PM
GARCIA PETER SChief Financial OfficerJan 28Option Exercise4.086,12825,0029,128Jan 29 04:15 PM
Pons JaumePresident & CEOJan 26Option Exercise0.9910,0009,900551,346Jan 28 06:01 AM
Graham G. WalmsleyDirectorDec 14Buy76.0020,0001,520,000995,000Dec 15 07:07 PM